BPC-157: What the Research Actually Shows

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a partial sequence of a larger protein naturally found in human gastric juice, and has a molecular weight of 1,419.5 daltons. The compound is also known by its pharmaceutical designations PL 14736 and Bepecin.

Unlike many research peptides, BPC-157 is notable for its stability across a wide pH range, including the highly acidic environment of the stomach. This property distinguishes it from other peptides that degrade rapidly in gastric fluid and is a key reason researchers have explored both injectable and oral routes of administration in preclinical studies.

The compound was first isolated and characterised by a research group at the University of Zagreb in Croatia, led by Professor Predrag Sikiric. The majority of the published preclinical literature on BPC-157 – over 100 studies spanning from 1993 to 2025 – originates from this group or its collaborators, a point that independent reviewers have flagged as a limitation when assessing the overall evidence base.

The bottom line: BPC-157 is a synthetic gastric peptide with a large preclinical research base but no completed large-scale human clinical trials, and it remains unapproved for therapeutic use in any country.

BPC-157 does not have a single confirmed mechanism of action. Instead, preclinical research has identified several overlapping biological pathways that the peptide appears to modulate. This multi-pathway activity is part of what makes the compound both scientifically interesting and difficult to characterise definitively.

Angiogenesis and VEGFR2 Signalling

One of the most studied proposed pathways involves BPC-157’s interaction with vascular endothelial growth factor receptor 2 (VEGFR2). In rodent models, the peptide appears to upregulate VEGFR2 signalling, promoting new blood vessel formation (angiogenesis) at injury sites. A 2025 systematic review by Vasireddi and colleagues in the American Journal of Sports Medicine confirmed that BPC-157 enhances growth hormone receptor expression and modulates pathways involved in cell growth and angiogenesis across three decades of published preclinical work.

Nitric Oxide System

BPC-157 interacts with the nitric oxide (NO) system through the Akt-eNOS signalling axis. This pathway is involved in vascular protection, endothelial function, and the regulation of blood pressure. Multiple preclinical studies have demonstrated that BPC-157 can counteract the effects of both NO-synthesis inhibitors (L-NAME) and NO-donors (L-arginine) in animal models, suggesting a modulatory rather than a simple stimulatory or inhibitory role.

Growth Hormone Receptor Upregulation

A study by Chang and colleagues, published in Molecules and Cells, demonstrated that BPC-157 dose-dependently and time-dependently increased growth hormone receptor (GHR) expression in rat tendon fibroblasts at both the mRNA and protein levels. When growth hormone was subsequently added to BPC-157-treated cells, it produced dose-dependent increases in cell proliferation and collagen secretion – suggesting BPC-157 may potentiate the body’s existing repair signalling rather than acting as a standalone growth factor.

Anti-Inflammatory Effects

Across multiple preclinical models, BPC-157 has been observed to reduce pro-inflammatory cytokines while stabilising epithelial and endothelial barrier functions. In gastrointestinal injury models, the peptide supported faster restoration of the intestinal mucosa and reduced intestinal permeability. Similar barrier-protective effects have been observed in vascular endothelium models.

The bottom line: BPC-157 appears to act through multiple overlapping pathways – primarily VEGFR2-mediated angiogenesis, nitric oxide modulation, growth hormone receptor upregulation, and anti-inflammatory signalling – but none of these mechanisms have been confirmed in human clinical studies.

BPC-157 has one of the largest preclinical literature bases of any research peptide. However, the quality and scope of that evidence requires careful evaluation. Here is what the research shows at each evidence tier.

Preclinical Evidence (Animal and In Vitro Studies)

A 2025 systematic review by Vasireddi, Hahamyan, Salata and colleagues – published in the American Journal of Sports Medicine – synthesised 36 studies spanning from 1993 to 2025. It found that BPC-157 improved functional, structural, and histological outcomes across multiple preclinical musculoskeletal models including tendon ruptures, ligament tears, muscle injuries, and fractures. Preclinical safety studies within the review showed no adverse effects across several organ systems, and the lethal dose (LD1) could not be established in toxicology studies – meaning researchers were unable to find a dose that caused death in animal subjects.

Human Evidence

Human evidence for BPC-157 is extremely limited. The compound was registered in early-phase clinical trials under two names: PL 14736 (for ulcerative colitis, in a Phase II enema study reported by Ruenzi in Gastroenterology in 2005) and Bepecin/PCO-02 (a Phase I pharmacokinetic safety study listed on ClinicalTrials.gov in 2015, which was subsequently cancelled before results were published). Neither study led to regulatory approval or produced published efficacy data.

The only published human data point identified by a 2025 systematic review is a small retrospective analysis in which 7 of 12 subjects with chronic knee pain reported relief lasting over six months following intra-articular injection. This represents extremely preliminary evidence – a retrospective case series without a control group.

Key Limitations of the Evidence

Independent reviewers have identified several concerns with the BPC-157 evidence base. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine noted that all published studies report positive or beneficial effects, suggesting possible publication bias. The concentration of research within a single laboratory group in Zagreb raises questions about independent reproducibility. And the obvious physiological differences between rodent models and human biology mean that preclinical results cannot be assumed to translate directly.

Evidence Tier	Volume	Summary
In vitro (cell studies)	Numerous	Consistent positive effects on fibroblast activity, collagen production, and cell migration
Preclinical (animal)	100+ studies (1993-2025)	Positive outcomes across musculoskeletal, GI, cardiovascular, and neurological models in rats and mice
Human clinical trials	1 cancelled Phase I, 1 Phase II (enema, UC)	No completed trials with published efficacy data
Human case reports	1 retrospective analysis (n=12)	7 of 12 knee pain subjects reported relief >6 months post-injection

The bottom line: BPC-157 has a substantial body of preclinical evidence across multiple tissue types, but the near-total absence of controlled human clinical data means its safety and efficacy in humans remains unverified.

BPC-157 is not approved for human therapeutic use in any country and is prohibited by WADA at all times. Its US compounding status is in flux following removal from FDA Category 2 in April 2026, with a formal PCAC review scheduled for July 2026.

United States (FDA)

BPC-157 is not an FDA-approved drug. On April 15, 2026, HHS confirmed its removal from Category 2 following withdrawal of its nominations. BPC-157 is now scheduled for formal evaluation at the PCAC meeting on July 23-24, 2026 (docket FDA-2025-N-6895), where the committee will assess whether it should be added to the 503A Bulks List. Its history of cancelled human trials – one Phase I withdrawn before producing results and one Phase II enema study that generated no published efficacy data – means the PCAC will be evaluating a compound with over 100 preclinical studies but virtually no controlled human evidence. For how the FDA’s compounding category system works and the full reclassification timeline, see our Category 1 vs Category 2 explainer and reclassification tracker.

United Kingdom (MHRA)

BPC-157 is not authorised for human use by the MHRA and cannot be legally prescribed or marketed as a medicine in the UK. It is not classified as a controlled substance under the Misuse of Drugs Act 1971, meaning it exists in a legal grey area – purchasable as a “research chemical” but not lawfully sold for human consumption. For a complete overview, see our guide to UK peptide legality.

Australia (TGA)

Australia became the first country to specifically schedule BPC-157 in June 2024, classifying it as a Schedule 4 (Prescription Only) substance. The TGA’s decision was supported by 21 of 22 public consultation responses and was driven by concerns about misuse in athletic, fitness, and anti-ageing markets. The TGA received 48 referrals for importation of BPC-157 between July 2022 and the scheduling decision. It is not listed on the Australian Register of Therapeutic Goods (ARTG). For the full Australian regulatory picture, see our Australian peptide law guide.

Jurisdiction	Status	Key Detail
United States (FDA)	Not approved – under PCAC review	Removed from Cat 2 (Apr 2026); PCAC hearing Jul 23, 2026
United Kingdom (MHRA)	Not authorised for human use	Not a controlled substance; grey-area “research chemical” sales
Australia (TGA)	Schedule 4 – Prescription Only	Specifically scheduled Jun 2024; first country to schedule BPC-157
WADA	Prohibited at all times	Category S0 (Non-Approved Substances); no TUE available

The bottom line: BPC-157 is not approved for human use in any country, is banned in competitive sport, and its US compounding pathway depends entirely on the outcome of the July 2026 PCAC review.

No clinical safety data exists for BPC-157 in humans. What we know about its safety profile comes entirely from preclinical animal studies and anecdotal user reports – neither of which can substitute for controlled human safety trials.

Preclinical Safety Data

In animal studies, BPC-157 has shown a favourable safety profile. Toxicology researchers were unable to identify a dose that caused mortality in animal subjects, and the 2025 ACG systematic review confirmed no adverse effects across several organ systems in preclinical models. BPC-157 has a short elimination half-life of approximately 7.9 to 30 minutes (measured in rats via IV and IM routes), is metabolised in the liver, and cleared by the kidneys.

Known Risks and Concerns

• No human safety data: The absence of completed human clinical trials means the human toxicity profile, drug interactions, and long-term effects are unknown.
• Immunogenicity risk: Some injectable peptides carry a risk of antibody formation, which can trigger allergic-type reactions. This has not been systematically studied for BPC-157 in humans.
• Angiogenesis concerns: Because BPC-157 promotes new blood vessel growth, there is a theoretical concern that it could support tumour vascularisation in individuals with existing cancers. No studies have directly tested this.
• Product quality: BPC-157 sold as a “research chemical” is not subject to pharmaceutical manufacturing standards. Contamination, incorrect labelling, and inaccurate peptide content are documented concerns across the unregulated peptide market.
• Sports sanctions: In 2024, 19-year-old US speed skater Kamryn Lute received a one-year ban after a supplement containing BPC-157 was recommended by a medical provider. A Canadian athlete received a four-year ineligibility period after non-analytical evidence verified BPC-157 use.

The bottom line: BPC-157 appears safe in animal studies with no observed adverse effects and no establishable lethal dose, but the complete absence of human clinical safety data means its risk profile in people is genuinely unknown.

BPC-157 is frequently discussed alongside several other research peptides studied for tissue repair and recovery. The key compounds worth understanding in context are:

• TB-500 (Thymosin Beta-4): A synthetic fragment of thymosin beta-4 that works through a different mechanism (actin regulation and cell migration) but is studied for similar tissue repair applications. Often discussed as a complementary compound to BPC-157 in preclinical research.
• Pentadeca Arginate (PA): A newer compound marketed as an arginine salt form of BPC-157, positioned by some vendors as a legal alternative following BPC-157’s Category 2 placement. Its regulatory status and evidence base differ from BPC-157 itself.
• GHK-Cu: A copper-binding tripeptide with its own preclinical evidence base for wound healing and collagen stimulation, operating through different pathways than BPC-157.
• KPV: An anti-inflammatory tripeptide derived from alpha-melanocyte-stimulating hormone, also under PCAC review at the same July 2026 meeting as BPC-157.

For a head-to-head comparison with its most commonly paired compound, see our full BPC-157 and TB-500 comparison. For a broader overview of the research peptide landscape for healing, see our healing peptides overview.

The most important upcoming event for BPC-157 is the PCAC meeting on July 23, 2026, where the FDA’s Pharmacy Compounding Advisory Committee will evaluate BPC-157-related bulk drug substances (both free base and acetate forms) for potential inclusion on the 503A Bulks List. Public comments submitted to docket FDA-2025-N-6895 by July 9, 2026 will be provided to committee members ahead of the meeting.

The broader context includes the RFK Jr. reclassification announcement from February 27, 2026, in which HHS Secretary Kennedy indicated that approximately 14 of 19 Category 2 peptides were expected to return to Category 1 status. BPC-157 is among those expected to be reclassified, but this has not been formally published by the FDA as of mid-2026.

Regardless of the compounding outcome, BPC-157 will remain unapproved by the FDA as a drug product. It will continue to be prohibited by WADA. And it will continue to lack the completed human clinical trials needed to establish definitive safety and efficacy in people.